It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
she also acknowledged the vaccines were not as effective as many were led to believe
what’s going to save you right now is Paxlovid
I knew these vaccines were not going to protect against infection. And I think we overplayed the vaccines.
50% of the people who died from the Omicron surge were older, vaccinated.
the key is testing and Paxlovid
Deborah Leah Birx is an American physician and diplomat who served as the White House Coronavirus Response Coordinator under President Donald Trump from 2020 to 2021. Birx specializes in HIV/AIDS immunology, vaccine research, and global health.
President's Emergency Plan for AIDS Relief
In January 2014, President Barack Obama nominated Birx to be the Ambassador-at-Large and U.S. Global AIDS Coordinator as part of the President's Emergency Plan for AIDS Relief (PEPFAR) program.[18][19]
Birx was confirmed by the Senate by voice vote on April 2, 2014,[20] and was sworn in two days later.[21] She described her role as ambassador to help meet the HIV prevention and treatment targets set by Obama in 2015 to end the AIDS epidemic by 2030.[22] Her role has focused on the areas of HIV/AIDS immunology, vaccine research, and global health issues around HIV/AIDS.[4] As part of her work with HIV prevention, Birx created a program called DREAMS (Determined, Resilient, Empowered, AIDS-free, Mentored and Safe), a public-private partnership focused on reducing infection rates among adolescent girls and young women.[23] PEPFAR management under Birx came under scrutiny in a February 2020 audit conducted by the State Department's Office of the Inspector General, with leadership of the program being described as "dictatorial" and "autocratic."[24]
The trial of 2,246 unvaccinated adults (who had mild to moderate COVID-19) found that the treatment "resulted in a risk of progression to COVID-19 that was 89 per cent lower than the risk with placebo, without evident safety concerns".
Researchers in a pivotal African clinical trial have been denied access to a key COVID-19 antiviral drug, frustrating efforts to test the treatment in African populations and in combination with therapies that could potentially expand its utility on the continent.
The Drugs for Neglected Diseases Initiative (DNDi) has asked Pfizer for supplies of its antiviral drug Paxlovid to use in the ANTICOV clinical trial, a large study in ten African countries that aims to find treatments for mild to moderate COVID-19 — particularly those that will work in resource-poor settings.
Hundreds of COVID trials could provide a deluge of new drugs
Earlier this year, DNDi requested enough Paxlovid to treat 1,000–2,000 ANTICOV participants, but says that Pfizer denied the request and stated that it already had plans to conduct similar trials. The details of those trials have not yet been made public, and Pfizer did not elaborate on such plans or the request from DNDi when asked about them by Nature. “We are committed to well-controlled, hypothesis-driven clinical studies that can provide data that will be accepted by global regulatory agencies,” the company said in a statement. “We’re focusing our efforts and resources in a way that maximizes availability of our overall supply.”
But Pfizer’s decision has dismayed public-health advocates. DNDi’s inability to obtain medicine for clinical trials compounds ongoing inequities in access to vaccines and treatments, including Paxlovid, in low- and middle-income countries, says Brook Baker, a law professor at Northeastern University in Boston, Massachusetts, who specializes in global access to medicines and vaccines. “This is a trial in a population that needs to be studied,” he says. “Why don’t we get on with it?”
It's all about money
Two drugs in one
Paxlovid is a combination of two drugs: nirmatrelvir and ritonavir. Nirmatrelvir blocks a SARS-CoV-2 protein that is important for viral replication; ritonavir acts in the liver to prevent the rapid breakdown of nirmatrelvir, and is a component of some therapies for treating HIV and hepatitis C infections.
In December, Pfizer, which is headquartered in New York City, announced that Paxlovid reduced the risk of hospitalization or death from COVID-19 by 88% when adults at high risk of developing severe disease were given the drug within five days of symptom onset1. The US Food and Drug Administration (FDA) followed soon after with an emergency-use authorization for the drug, and researchers hailed the development of an oral antiviral that didn’t have to be administered in hospital.
But nirmatrelvir is in very short supply, and that put low- and middle-income countries at a disadvantage in the ensuing bidding war for Paxlovid. Pfizer has said it can make up to 120 million courses of the treatment by the end of the year. Of those, the company has promised up to four million courses to the United Nations children’s charity UNICEF for distribution in low- and middle-income countries. “We are in continued conversations with a number of private partners and international organizations to provide Paxlovid to lower income countries,” Pfizer said in a statement.
From 1980 to 1989, Birx worked as a physician at the Walter Reed Army Medical Center.[15] In 1981, Birx completed a one-year internship and did a two-year residency in internal medicine. From 1983 to 1986, she completed two fellowships in clinical immunology in the areas of allergies and diagnostics, where she worked in Anthony Fauci's lab.[5] From 1985 to 1989, Birx was the assistant chief of the Walter Reed Allergy/Immunology Service. Birx started her career as a clinician in immunology, eventually focusing on HIV/AIDS vaccine research.[5][15]
From 1986 to 1989, Birx worked at the National Institutes of Health as an investigator specializing in cellular immunology.[15]
Birx returned to Walter Reed, where from 1989 to 1995 she worked in the Department of Retroviral Research, first as an assistant chief and then as chief of the division. She was lab director in HIV-1 Vaccine Development for a year. Birx became the director of the United States Military HIV Research Program at the Walter Reed Army Institute of Research, a position she held for nine years, from 1996 to 2005. In that position, Birx led the HIV vaccine clinical trial of RV 144, the first supporting evidence of any vaccine being effective in lowering the risk of contracting HIV.[15]
In March 2020, Birx became a board member of the Global Fund to Fight AIDS, Tuberculosis and Malaria.[
The fifth replenishment meeting took place September 2016 in Montreal, Canada, and was hosted by Canadian Prime Minister Justin Trudeau. Donors pledged US$12.9 billion (at 2016 exchange rates) for the 2017–2019 period.[34]
France held the sixth replenishment meeting in 2019 in Lyon, hosted by President Emmanuel Macron raising US$14.02 billion for 2020–2022.[35] This was the largest amount ever raised for a multilateral health organisation, and the largest amount for the Global Fund.[36]
The seventh replenishment meeting will be hosted by the United States in 2022 hosted by President Joe Biden, announced by Secretary of State Antony Blinken.
originally posted by: Randyvine2
a reply to: trollz
Well where are all the vax addicts? Hung out to dry?
I just posted a reply yesterday claiming "The walls are closing in"
on them and now I guess they're behind the wall of google.
Forever searching.
originally posted by: ancientlight
a reply to: trollz
So, now that they admit the 'vacccines' don't stop the spread of infection, are they going to remove the current 'vaccine' travel mandates for non-US travelers to the US ?
originally posted by: carewemust
Did she tell FAUCI? Did Fauci KNOW? What did she tell President Trump?
It's important to have answers to these questions for the upcoming Congressional probe and criminal referrals.
Birx is busy promoting her new book, and it contains several brazen admissions of dishonesty, including misleading the Trump administration by disobeying orders and altering reports.
Birx dishonestly and illegally changed the guidance and instructions issued by people senior to her, in particular those of President Trump.
originally posted by: Randyvine2
a reply to: trollz
Well where are all the vax addicts? Hung out to dry?
I just posted a reply yesterday claiming "The walls are closing in"
on them and now I guess they're behind the wall of google.
Forever searching.